EMD-25163
HtrA1S328A:Fab15H6.v4 complex
EMD-25163
Single-particle3.3 Å

Map released: 07/09/2022
Last modified: 13/11/2024
Sample Organism:
Homo sapiens
Sample: HtrA1PD/SA bound by Fab15H6.v4 at LoopA epitope
Fitted models: 7sjo (Avg. Q-score: 0.405)
Deposition Authors: Gerhardy S
,
Green E
Sample: HtrA1PD/SA bound by Fab15H6.v4 at LoopA epitope
Fitted models: 7sjo (Avg. Q-score: 0.405)
Deposition Authors: Gerhardy S

Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration.
Gerhardy S
,
Ultsch M,
Tang W
,
Green E,
Holden JK
,
Li W,
Estevez A,
Arthur C,
Tom I,
Rohou A
,
Kirchhofer D
(2022) Nat Commun , 13 , 5222 - 5222





(2022) Nat Commun , 13 , 5222 - 5222
Abstract:
The trimeric serine protease HTRA1 is a genetic risk factor associated with geographic atrophy (GA), a currently untreatable form of age-related macular degeneration. Here, we describe the allosteric inhibition mechanism of HTRA1 by a clinical Fab fragment, currently being evaluated for GA treatment. Using cryo-EM, X-ray crystallography and biochemical assays we identify the exposed LoopA of HTRA1 as the sole Fab epitope, which is approximately 30 Å away from the active site. The cryo-EM structure of the HTRA1:Fab complex in combination with molecular dynamics simulations revealed that Fab binding to LoopA locks HTRA1 in a non-competent conformational state, incapable of supporting catalysis. Moreover, grafting the HTRA1-LoopA epitope onto HTRA2 and HTRA3 transferred the allosteric inhibition mechanism. This suggests a conserved conformational lock mechanism across the HTRA family and a critical role of LoopA for catalysis, which was supported by the reduced activity of HTRA1-3 upon LoopA deletion or perturbation. This study reveals the long-range inhibition mechanism of the clinical Fab and identifies an essential function of the exposed LoopA for activity of HTRA family proteases.
The trimeric serine protease HTRA1 is a genetic risk factor associated with geographic atrophy (GA), a currently untreatable form of age-related macular degeneration. Here, we describe the allosteric inhibition mechanism of HTRA1 by a clinical Fab fragment, currently being evaluated for GA treatment. Using cryo-EM, X-ray crystallography and biochemical assays we identify the exposed LoopA of HTRA1 as the sole Fab epitope, which is approximately 30 Å away from the active site. The cryo-EM structure of the HTRA1:Fab complex in combination with molecular dynamics simulations revealed that Fab binding to LoopA locks HTRA1 in a non-competent conformational state, incapable of supporting catalysis. Moreover, grafting the HTRA1-LoopA epitope onto HTRA2 and HTRA3 transferred the allosteric inhibition mechanism. This suggests a conserved conformational lock mechanism across the HTRA family and a critical role of LoopA for catalysis, which was supported by the reduced activity of HTRA1-3 upon LoopA deletion or perturbation. This study reveals the long-range inhibition mechanism of the clinical Fab and identifies an essential function of the exposed LoopA for activity of HTRA family proteases.